Next Article in Journal
Unconventional Secretion of Heat Shock Proteins in Cancer
Next Article in Special Issue
Innovative Clinical Perspectives for CIK Cells in Cancer Patients
Previous Article in Journal
Effect of High Glucose Levels on White Adipose Cells and Adipokines—Fuel for the Fire
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2017, 18(5), 945;

CIK Cells and HDAC Inhibitors in Multiple Myeloma

Department of Internal Medicine III, Center for Integrated Oncology (CIO), University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, Sigmund-Freud-Straße 25, 53105 Bonn, Germany
Hochschule Bonn-Rhein-Sieg, Von-Liebig-Straße 20, 53359 Rheinbach, Germany
Author to whom correspondence should be addressed.
Academic Editor: Michael R. Hamblin
Received: 8 February 2017 / Revised: 7 April 2017 / Accepted: 25 April 2017 / Published: 29 April 2017
(This article belongs to the Special Issue Natural Killer T (NKT) Cells)
Full-Text   |   PDF [1628 KB, uploaded 2 May 2017]   |  


Multiple myeloma is the second most common hematological malignancy. Despite all the progress made in treating multiple myeloma, it still remains an incurable disease. Patients are left with a median survival of 4–5 years. The combined treatment of multiple myeloma with histone deacetylase inhibitors and cytokine-induced killer cells provides a promising targeted treatment option for patients. This study investigated the impact of a combined treatment compared to treatment with histone deacetylase inhibitors. The experiments revealed that a treatment with histone deacetylase (HDAC) inhibitors could reduce cell viability to 59% for KMS 18 cell line and 46% for the U-266 cell line. The combined treatment led to a decrease of cell viability to 33% for KMS 18 and 27% for the U-266 cell line, thus showing a significantly better efficacy than the single treatment. View Full-Text
Keywords: multiple myeloma; cytokine-induced killer cells; CIK cells; histone deacetylase inhibitors; immunotherapy; cancer treatment multiple myeloma; cytokine-induced killer cells; CIK cells; histone deacetylase inhibitors; immunotherapy; cancer treatment

Figure 1a

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Stephan, D.; Weiher, H.; Schmidt-Wolf, I.G. CIK Cells and HDAC Inhibitors in Multiple Myeloma. Int. J. Mol. Sci. 2017, 18, 945.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top